The Ability of Thrombin Inhibitors to Reduce the Thrombin Activity Generated in Plasma on Extrinsic and Intrinsic Activation

Summary

In a thrombin generation test with continuous registration of thrombin activity in plasma we studied the ability of a variety of thrombin inhibitors of different type and mechanism of action to influence the activity of thrombin after activation of the coagulation system. Depending on the inhibitor, the peak of thrombin activity is delayed and/or reduced.

By blocking the active site of generated thrombin inhibitors cause a concentration dependent reduction of the thrombin peak and inhibit feed-back reactions of thrombin resulting in a delay of thrombin generation. Highly potent synthetic active-site directed inhibitors (K_i ≤ 20 nM) reduce the thrombin activity formed in plasma after extrinsic or intrinsic activation with the same efficiency (IC₅₀ 0.1 - 0.6 μM) as hirudin. The delay and reduction of thrombin generation by inhibitors of the anion-binding exosite 1 of thrombin is only attributed to an inhibition of feed-back reactions of thrombin. For a 50% reduction of thrombin activity in plasma by this type of inhibitors relatively high concentrations were determined.

• References

• 1 Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-624
• 2 Walz DA, Anderson GF, Ciaglowski RE, Aiken M, Fenton IIJW. Thrombin-elicited contractile responses of aortic smooth muscle. Proc Soc Exp Biol Med 1985; 180: 518-526
• 3 Scully MF. Kinetic considerations on the physiologic control of thrombin and factor Xa. Semin Thromb Hemost 1992; 18: 218-223
• 4 Stone SR, Tapparelli C. Thrombin inhibitors as antithrombotic agents:the importance of rapid inhibition. J Enzyme Inhibition 1995; 9: 3-15
• 5 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-3188
• 6 Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-1012
• 7 Kelly AB, Hanson SR, Dunwiddie CT, Harker LA. Safe lasting interruption of arterial thrombosis by transient intravenous administration of tick anticoagulant peptide TAP. Circulation 1992; 86 suppl: 411
• 8 Lindahl AK, Wildgoose P, Lumsden AB, Allen R, Kelly AB, Harker LA, Hanson SR. Active-site-inhibited factor VIIa blocks tissue factor activity and prevents arterial thrombus formation in baboons. Circulation. 1993; 88 suppl: 417
• 9 Gast A, Tschopp TB, Baumgartner HR. Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler Thromb 1994; 14: 1466-1474
• 10 Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23
• 11 Bajusz S, Barabas E, Tolnay P, Szell E, Bagdy D. Inhibition of thrombin and trypsin by tripeptide aldehydes. Int J Pept Protein Res 1978; 12: 217-221
• 12 Bagdy D, Barabas E, Bajusz S, Szell E, Szabo G, Valko I. Studies on the anticoagulant effect and pharmacokinetics of N-methyl-D-Phe-Pro-Arg-H (GYKI 14 766). Thromb Haemost 1989; 62: 535
• 13 Kettner C, Shaw E. D-Phe-Pro-Arg-CH₂Cl – a selective affinity label for thrombin. Thromb Res 1979; 14: 969-973
• 14 Neises B, Tamus C. Thrombin inhibition by the tripeptide trifluoromethyl ketone D-Phe-Pro-Arg-CF₃(MDL 73756). Thromb Haemost 1991; 65: 2155
• 15 Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990; 265: 18289-18297
• 16 Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, Ninomiya K, Maruyama A, Sugano M, Tamao Y. Potent inhibition of thrombin by the newly synthesized arginine derivative Nr, 805:the importance of the stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-446
• 17 Stürzebecher J, Markwardt F, Voigt B, Wagner G, Walsmann P. Cyclic amides of Nαarylsulfonyl-aminoacylated 4-amidinophenylalanine – tight binding inhibitors of thrombin. Thromb Res 1983; 29: 635-642
• 18 Stürzebecher J, Hauptmann J, Prasa D, Wikström P, Vieweg H. Synthesis and structure-activity relationships of potent thrombin inhibitors derived from piperazides of 3-amidinophenylalanine. J Med Chem. 1997. in press
• 19 Hilpert K, Ackermann J, Banner DW, Gast A, Gubemator K, Schmid G, Tschopp TB, van de Waterbeemd H. The development of potent and highly selective thrombin inhibitors. Europ J Med Chem 1995; 30 Suppl: 132S-138S
• 20 Dickneite G, Seiffge D, Diehl KH, Reers M, Czech J, Weinmann E, Hoffmann D, Stüber W. Pharmacological characterization of a new 4-ami-dinophenylalanine thrombin inhibitor (CRC 220). Thromb Res 1995; 77: 357-368
• 21 Mack H, Pfeiffer T, Homberger W, Böhm HJ, Höffken HW. Design synthesis and biological activity of novel rigid amidinophenylalanine derivatives as inhibitors of thrombin. J Enzyme Inhibition 1995; 9: 73-86
• 22 Mao SJT, Yates MT, Owen TJ, Krstenansky JL. Interaction of hirudin with thrombin:identification of a minimal binding domain of hirudin that inhibits clotting activity. Biochemistry 1988; 27: 8170-8173
• 23 Naski MC, Fenton JW, Maraganore JM, Olson ST, Shafer JA. The COOH-terminal domain of hirudin. J Biol Chem 1990; 265: 13484-13489
• 24 Payne MH, Krstenansky JL, Yates MT, Mao SJT. Positional effects of sulfation in hirudin and hirudin PA related anticoagulant peptides. J Med Chem 1991; 34: 1184-1187
• 25 Homberger W, Rübsamen K, Laux V, Schwarz M, Bernard H. Antithrombin and antithrombotic properties of a new decapeptide thrombin exosite inhibitor (LU 58463) – comparison with hirudin. Thromb Haemost 1993; 69: 1300
• 26 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton IJW. Design and characterization of hirulogs:A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7107
• 27 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-462
• 28 Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-468
• 29 Hemker HC, Béguin S. Mode of action of heparin and related drugs. Semin Thromb Hemost 1991; (Suppl. 01) 29-34
• 30 Béguin S, Wielders S, Lormeau J-C, Hemker HC. The mode of action of CY216 and CY222 in plasma. Thromb Haemost 1992; 67: 33-41
• 31 Lormeau J-C, Herault JP. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin low molecular weight heparin and the synthetic AT III-binding pentasaccharide. Thromb Haemost 1993; 69: 152-156
• 32 Kessels H, Béguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood – the effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83
• 33 Verhallen PFJ, Gehrmann G, Prasa D, Stiirzebecher J. Measurement of thrombin generation in human plasma by two different methods (subsample/continuous):characterization of different anticoagulants. Thromb Haemost 1995; 73: 1247
• 34 Gast A, Tschopp TB. Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46-6240) recombinant hirudin and heparin in human plasma. Blood Coag Fibrinol 1995; 6: 553-560
• 35 Walsmann P. Über die Reinigung von Thrombinpräparaten. Pharmazie 1968; 23: 401-402
• 36 Richter P, Wagner G. Synthesen von 4-Amidinophenylbrenztraubensäure (APPA). Teil 1. Pharmazie 1973; 28: 514-519
• 37 Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953; 55: 170-171
• 38 Henderson PJF. A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interaction with tightly bound inhibitors. Biochem J 1972; 127: 321-333
• 39 Neises B. The synthesis and anticoagulant activity of novel peptidylfluoroalkanes. Adv Exp Med Biol 1993; 340: 185-188
• 40 Kettner C, Shaw E. Inactivation of trypsin-like enzymes with peptides of arginine chloromethyl ketones. Methods Enzymol 1981; 80: 826-842
• 41 Deadman J, Claeson G, Scully MF. Structure/function aspects of neutral PI residue peptide inhibitors of thrombin. J Enzyme Inhibition 1995; 9: 29-41
• 42 Odake S, Kam C-M, Powers JC. Inhibition of thrombin by arginine-containing peptide chloromethyl ketones and bis chloromethyl ketone-albumin conjugates. J Enzyme Inhibition 1995; 9: 17-27
• 43 Oleksyszyn J, Boduszek B, Kam C-M, Powers JC. Novel amidine-containing peptidyl phosphonates as irreversible inhibitors for blood coagulation and related serine proteases. J Med Chem 1994; 37: 226-231
• 44 Tapparelli C, Metternich R, Ehrhardt C, Zurini M, Claeson G, Scully MF, Stone SR. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J Biol Chem 1993; 268: 4734-4741
• 45 Fusetani N, Nakao Y, Matsunaga S. Nazumamide A a thrombin-inhibitory tetrapeptide from a marine sponge theonella sp. Tetrahedron Lett 1991; 32: 7073-7074
• 46 Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052
• 47 Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74: 1021-1024
• 48 Ofosu FA, Modi GJ, Hirsh J, Buchanan MR, Blajchman MA. Mechanism for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ann N Y Acad Sci 1986; 485: 41-55
• 49 Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive feed-back reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 1987; 243: 579-588
• 50 Markwardt F, Hoffmann J, Körbs E. The influence of synthetic thrombin inhibitors on the thrombin-antithrombin reaction. Thromb Res 1973; 2: 343-348
• 51 Griffith MJ, Kingdon HS, Lundblad RL. Inhibition of the heparin-anti-thrombin III/thrombin reaction by active site blocked-thrombin. Biochem Biophys Res Commun 1979; 87: 686-692
• 52 Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 1989; 264: 8692-8698
• 53 Krstenansky JL, Owen TJ, Yates MT, Mao SJT. The C-terminal binding domain of hirullin PI8 – Antithrombin activity and comparison to hirudin peptides. FEBS Lett. 1990; 269: 425-429